anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In general, the invention features a substantially pure polypeptide which is a fragment or analog of cartilage matrix protein, the polypeptide being capable of binding collagen. In various preferred embodiments the polypeptide includes CMP-1 or CMP-2; the polypeptide is all or part of CMP-1; the polypeptide is all or part of CMP-2; and the polypeptide is all or part of CMP-1 and CMP-2.  In a related aspect, the invention features a method for forming collagen fibrils. The method includes contacting cartilage matrix protein with collagen. In another related aspect, the invention features a method for delivering a compound to collagenous tissue, the method includes administering to a patient the compound linked to a polypeptide which includes CMP-1 or CMP-2. In another aspect, the invention features molecular conjugate which includes a collagen-binding fragment of cartilage matrix protein and an imaging or therapeutic agent.
OBJECTIVE: To investigate racial inequities in the use of therapeutic hypothermia (TH) and outcomes in infants with hypoxic-ischemic encephalopathy (HIE).
STUDY DESIGN: We queried an administrative birth cohort of mother-baby pairs in California from 2010 through 2019 using International Classification of Diseases codes to evaluate the association between race and ethnicity and the application of TH in infants with HIE. We identified 4779 infants with HIE. Log-linear regression was used to calculate risk ratios (RR) for TH, adjusting for hospital transfer, rural location, gestational age between 35 and 37 weeks, and HIE severity. Risk of adverse infant outcome was calculated by race and ethnicity and stratified by TH.
RESULTS: From our identified cohort, 1338 (28.0%) neonates underwent TH. White infants were used as the reference sample, and 410 (28.4%) received TH. Black infants were significantly less likely to receive TH with 74 (20.0%) with an adjusted risk ratio (aRR) of 0.7 (95% CI 0.5-0.9). Black infants with any HIE who did not receive TH were more likely to have a hospital readmission (aRR 1.36, 95% CI 1.10-1.68) and a tracheostomy (aRR 3.07, 95% CI 1.19-7.97). Black infants with moderate/severe HIE who did not receive TH were more likely to have cerebral palsy (aRR 2.72, 95% CI 1.07-6.91).
CONCLUSIONS: In this study cohort, Black infants with HIE were significantly less likely to receive TH. Black infants also had significantly increased risk of some adverse outcomes of HIE. Possible reasons for this inequity include systemic barriers to care and systemic bias.
Patients will be recruited from those presenting with hematuria and undergoing investigative cystoscopy for the determination of possible urothelial carcinoma. This includes patients referred via imaging or from other departments for assessment of hematuria. Microscopic hematuria is defined as \> 3 red blood cells per high-powered microscopy field for a properly collected urine sample.
Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis. Although immunotherapy is being explored as a potential treatment option for patients with GBM, it is unclear whether systemic immunotherapy can reach and modify the tumor microenvironment in the brain. We evaluated immune characteristics in patients receiving the anti-PD-1 immune checkpoint inhibitor nivolumab 1 week prior to surgery, compared with control patients receiving salvage resection without prior nivolumab treatment. We observed saturating levels of nivolumab bound to intratumorally and tissue-resident T cells in the brain, implicating saturating levels of nivolumab reaching brain tumors. Following nivolumab treatment, significant changes in T-cell activation and proliferation were observed in the tumor-resident T-cell population, and peripheral T cells upregulated chemokine receptors related to brain homing. A strong nivolumab-driven upregulation in compensatory checkpoint inhibition molecules, i.e., TIGIT, LAG-3, TIM-3, and CTLA-4, was observed, potentially counteracting the treatment effect. Finally, tumor-reactive tumor-infiltrating lymphocytes (TIL) were found in a subset of nivolumab-treated patients with prolonged survival, and neoantigen-reactive T cells were identified in both TILs and blood. This indicates a systemic response toward GBM in a subset of patients, which was further boosted by nivolumab, with T-cell responses toward tumor-derived neoantigens. Our study demonstrates that nivolumab does reach the GBM tumor lesion and enhances antitumor T-cell responses both intratumorally and systemically. However, various anti-inflammatory mechanisms mitigate the clinical efficacy of the anti-PD-1 treatment.
Table 4. Description   


  


Clobazam is a white or almost white crystalline powder; is freely soluble in dichloromethane. The melting range of clobazam is from 182ºC to 185ºC. The molecular formula is C 16H 13ClN 2O 2 and the molecular weight is 300.74.   
Clobazam is available for oral administration as an off white suspension containing clobazam at a concentration of 2.5 mg/mL. Inactive ingredients include citric acid monohydrate, dibasic sodium phosphate anhydrous, magnesium aluminum silicate, maltitol solution, methylparaben, polysorbate 80, propylene glycol, propyl paraben, purified water, simethicone emulsion, strawberry flavor, sucralose and xanthan gum.
Participants in the tele-physical therapy group underwent tele-physical therapy sessions which includes an internet-based video conference under the supervision of physical therapists. Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm-up, 60 minutes of training and 10 minutes of a cool-down phase. The participants in the tele physical therapy group received training four times a week, for 8 weeks, each session lasted for 60 minutes.
<P>PROBLEM TO BE SOLVED: To provide a food containing viable lactic acid bacteria, needing neither costly process nor material and efficiently deliverable to the intestine through its oral administration.  <P>SOLUTION: A nucleic acid complex for protecting viable lactic acid bacteria from gastric juice comprising a nucleic acid, one or more gelatinizers and water is provided. A nucleic acid complex mixture with viable lactic acid bacteria protected therein comprising said nucleic acid complex and an emulsified product prepared by emulsifying a liquid containing the viable lactic acid bacteria with an emulsifier and fat and oil is provided. A method for producing said nucleic acid complex mixture comprises mixing said emulsified product with said nucleic acid complex. A method for protecting lactic acid bacteria from gastric juice is also provided. In the above, the nucleic acid complex is preferably such one that the nucleic acid is a DNA derived from living body waste in particular and the gelatinizer(s) comprises gelatin and carrageenan. Further, said emulsifier and oil and fat preferably comprise lecithin and cacao butter respectively.  <P>COPYRIGHT: (C)2004,JPO
The sealable shaped body for packaging oral biologics such as oral vaccines, formed from a thermoformable, biodegradable film composite (1), is claimed, where the film composite comprises three layers. The layers are connected with a laminating adhesive layer (3). One of exterior layers is formed as a sealant layer (2). The other exterior layer consists of a non-woven fabric. A middle layer is a biodegradable barrier layer (4). The sealant layer, the barrier layer, the laminating adhesive layer and a layer made of non-woven fabric consist of a native biopolymer. The sealable shaped body for packaging oral biologics such as oral vaccines, formed from a thermoformable, biodegradable film composite (1), is claimed, where the film composite comprises three layers. The layers are connected with a laminating adhesive layer (3). One of exterior layers is formed as a sealant layer (2). The other exterior layer consists of a non-woven fabric. A middle layer is a biodegradable barrier layer (4). The sealant layer, the barrier layer, the laminating adhesive layer and a layer made of non-woven fabric consist of a native biopolymer, a bio-based polymer and/or a petroleum-based polymer. The laminating adhesive is a biodegradable polyurethane adhesive, and has a thickness of 3 mu m. The exterior layer made of non-woven material has a thickness of 0.3 mm. The barrier layer has a thickness of 20 mu m. The non-woven material consists of fleece, and has a fiber length of 4 cm. The barrier layer has a barrier effect against fluids, water, air, oxygen and carbon dioxide. The sealant layer has a thickness of 50 mu m. The film composite contains two barrier layers, and has a tensile strength of more than 50 Newton, a tear ability of more than 10 Newton, a bond strength of more than 1.7 Newton, a transmissivity of water vapor (greater than 0.30 g/m 2>/24 hours) at 23[deg] C and 50% of relative humidity, a transmissivity of carbon dioxide (greater than 1.44 cm 3>/m 2>/24 hours) and/or a transmissivity of oxygen (greater than 0.65 cm 3>/m 2>/24 hours). The film composite is present in the form of trajectories. The film composite of the respective trajectories is different or identical. An independent claim is included for a method for preparing a sealable shaped body.
Within the scope of this research, sexual counseling, based on the extended (EX-PLISSIT) model was offered to women for 6-10 weeks (until a solution was achieved). The EX-PLISSIT model is based on the core concepts of the PLISSIT model. The PLISSIT model is an effective, convenient and cost effective counseling method. This model was designed by Annon (1976) and includes the stages permission, limited ınformation, specific recommendations and intensive therapy. It is known that the PLISSIT model is effective for SD. The PLISSIT Model has been updated and expanded because it offers one-way, passive interaction. While counseling is linear in the PLISSIT model, it is feedback-oriented in the EX-PLISSIT model. This is one of the reasons why the EX-PLISSIT model is superior to the PLISSIT model. Unlike PLISSIT's linear mode; The EX-PLISSIT model is done in a cyclical manner. In other words, it is an interactive and repetitive model. All interventions must begin with "Permission." Each stage of "Limited Information", "Special Recommendation" and "Intensive Therapy" is supported by "Allowing". Thus, the interaction between counselors and clients is improved. While in the PLISSIT model, a direct transition can be made from one step to another, in the EX-PLISSIT model, the permission stage is at the center of the other stages and techniques such as review, and examination are used to increase the client's self-awareness. The EX-PLISSIT model is a practical guide for nursing research and practice.
INTRODUCTION: The role of lipid metabolism in lung adenocarcinoma (LUAD) is not completely researched. Lipid metabolism reprogramming is a characteristic of malignancies and contributes to carcinogenesis and progression. The transcriptome and scRNA- seq data and clinical information were downloaded from the public databases.
METHODS: Lipid metabolism pathways were collected from the MSigDB database, and molecular subtypes were classified based on lipid metabolism features via consensus clustering. The bidirectional crosstalk between immune cells and malignant cells was analyzed. Differences in lipid metabolism at the single-cell level and their correlation with the tumor microenvironment (TME) were also studied. LUAD patients were classified into two subtypes, showing distinct mutation and lipid metabolism features based on lipid metabolism characteristics. Meanwhile, significant differences in the overall survival, clinical characteristics, and immune landscape were observed between the two subtypes. We also found that clust1 had higher oxidative stress status. There were 116 differentially expressed genes between the two subtypes, which were significantly associated with cell cycle progression. We identified 4001 immune cells, including 483 malignant cells and 3518 normal cells, and found active intercellular communication and significant differences in lipid metabolism characteristics between the malignant cells and normal cells. Furthermore, several lipid metabolism pathways were found to be associated with TME factors, including hypoxia and angiogenesis.
RESULT: The current findings indicated that lipid metabolism was involved in the development and cellular heterogeneity of LUAD and revealed widespread reprogramming across multiple cellular elements in the TME of LUAD.
CONCLUSION: This characterization improved the current understanding of tumor biology and enabled the identification of novel targets for immunotherapy.
Participants will be provided with 20 grams of creatine monohydrate per day (100 grams total) in sealed and unopened packages (5 grams in each package). Participants will be asked to complete their supplementation protocol (20 grams/day) by mixing 5 grams of creatine monohydrate powder into water 4 times a day or 10 grams of creatine monohydrate powder into water twice a day. This supplementation will occur after a baseline visit in which participants consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial. Following the 5 days of supplementation participants will come back and consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial.
The EMA intervention uses twice-a-day interactive questions for emotion tracking including type of emotion, intensity of emotion, trigger to emotion and response to emotion through an Iphone app designed for the study. The study users receive individualized feedback about their daily reporting of emotions, sleep and stress.The study tracking is for 14 days.
The invention relates to a gingiva pain-relieving, bleeding-stopping, and inflammation-eliminating composition which is used after tooth extraction or when teeth are suffered from pain, bleeding, or inflammations. The composition is composed of the components of: alcohol, carbolic acid, camphor sand, clove oil, and zinc oxide, which are mixed into a paste. When in use, the composition is coated on a gingival afflicted part with a coating method, such that pain relieving, bleeding stopping, and inflammation eliminating effects can be provided. When the composition is used for preventing the teeth problems, the composition can be mixed with toothpaste, and the mixture can be used daily in tooth brushing. Or, the composition can be mixed with mouthwash, and the mixture can be used daily in mouth washing. With the composition, gingival pain can be eliminated, and gingival bleeding or inflammation can be prevented.
The present invention discloses polypeptides for use in vaccines against pertussis and parapertussis. The polypeptides of the invention are derived from the  Bordetella pertussis  pertactin. Preferably, the polypeptides of the invention comprise sequences from region 1 of pertactin, in particular they comprise one or more “GGFGP” or “GGAVP” repeats. Alternatively the polypeptides of the invention have a pertactin sequence from which part or all of region 1 or region 2 is deleted. The polypeptides of the invention are incorporated in compositions that are useful as vaccines for human and veterinary purposes. The invention further discloses antibodies against the pertactin-derived polypeptides of the invention.
A topical germicidal composition comprising: 50 - 85 %wt. of an alcohol constituent comprising one or more C1-C4 monohydric alcohols; 0.01 - 5%wt. of a film forming constituent based- on one or more celluloses or cellulose derivatives, 0.01— 25%wt. of a humectant, preferably glycerine; 0.0 1 - 5%wt. of an opacifier constituent; optionally but preferably a Polyquaternium-type polymer or material; optionally one or more further constituents for improving the aesthetic or other technical characteristics of the invention, with the balance- of the composition, up to about 30%wt. of water, wherein the composition is characterized that it is flowable and preferably also exhibits an initial viscosity ("as mixed") of at least about 10 cPs measured at 25 °C, and subsequent to being stored at elevated temperatures and/or extended time intervals are retained as a single phase composition and do not split or separate into two or more phases, and further, the compositions provide a topical germicidal benefit when applied to the skin or parts of the body.
Participants receive cyclophosphamide, autologous NY-ESO-1-specific CD8-positive T lymphocytes, and aldesleukin as in Cohort 0. Participants also receive dendritic cell-targeting lentiviral vector ID-LV305 ID on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
OBJECTIVE: Tubular retractors are increasingly used due to their low complication rates, providing easier access to lesions while minimizing trauma from brain retraction. Our study presents the most extensive series of cases performed by a single surgeon aiming to assess the effectiveness and safety of a transcortical-transtubular approach for removing intracranial lesions.
METHODS: We performed a retrospective review of patients who underwent resection of an intracranial lesion with the use of tubular retractors. Electronic medical records were reviewed for patient demographics, preoperative clinical deficits, diagnosis, preoperative and postoperative magnetic resonance imaging (MRI) scans, lesion characteristics including location, volume, extent of resection (EOR), postoperative complications, and postoperative deficits.
RESULTS: 112 transtubular resections for intracranial lesions were performed. Patients presented with a diverse number of pathologies including metastasis (31.3 %), GBM (21.4 %), and colloid cysts (19.6 %) The mean pre-op lesion volume was 14.45 cm3. A gross total resection was achieved in 81 (71.7 %) cases. Seventeen (15.2 %) patients experienced early complications which included confusion, short-term memory difficulties, seizures, meningitis and motor and visual deficits. Four (3.6 %) patients had permanent complications, including one with aphasia and difficulty finding words, another with memory loss, a third with left-sided weakness, and one patient who developed new-onset long-term seizures. Mean post-operative hospitalization length was 3.8 days.
CONCLUSION: Tubular retractors provide a minimally invasive approach for the extraction of intracranial lesions. They serve as an efficient tool in neurosurgery, facilitating the safe resection of deep-seated lesions with minimal complications.
During Combination Therapy, farletuzumab will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6, cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive farletuzumab as monotherapy until disease progression.
Folic Acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Daily doses of 0.1 mg or more of folic acid (vitamin B9) may obscure pernicious anemia. Hematologic improvement can occur while neurological damage progresses. Exclusive use of folic acid to treat vitamin B12-deficient macrocytic anemia can lead to progressive and irreversible neurological damage. Vitamin B12 deficiency allowed to progress for over 3 months may cause permanent spinal cord lesions. Doses of vitamin B12 exceeding 10 mcg daily may produce hematologic response in patients with vitamin B9 deficiency. Indiscriminate administration may mask the true diagnosis.
With nearly 4 million people in the United States, and an estimated 170-200 million people worldwide, the hepatitis C virus (HCV) represents a clear and significant public health issue. Unfortunately, for most people infected with HCV (70%-85%) spontaneous resolution is uncommon and 60% to 80% of patients with acute hepatitis C infection develop chronic hepatitis. This randomized trial focuses on defining the effect of treatment of acute HCV on prevention of chronic hepatitis in addition to optimization of the treatment regimen, onset and the length of peginterferon alpha therapy in acute hepatitis C infections. This randomized, multi-center prospective study assesses the efficacy of peginterferon in acute hepatitis. We will also compare differences in sustained viral response rates in patients with acute hepatitis C starting treatment at 8, 12, or 24 weeks. We will also compare the efficacy of 8, 12 or 24 weeks therapy with PEG-IFN-alpha. All eligible patients are enrolled and screened for an initial observation period starting from the time of their first positive HCV-RNA-PCR, during which bi-weekly serum ALT and HCV-RNA subjects were performed. Patients who did not resolve spontaneously (loss of HCV-RNA without treatment) by the end of the observation period were randomly assigned to receive PEG-IFN-alpha at the assigned onset and/or duration. Patients who do not consent to therapy at enrollment are included as a non-randomized comparison group. All subjects with SVR were followed for 48 weeks after the follow-up at 24 weeks when SVR was determined.
* For subcutaneous injection only.
  * SUSTOL is intended for administration by a health care provider.
  * SUSTOL is supplied as a refrigerated kit consisting of a single-dose, pre-filled, sterile syringe, a special thin walled 18 Ga 5/8" administration needle, two syringe warming pouches, and a Point Lok® needle protection device. See the SUSTOL Instructions for Use included in the kit for complete administration instructions with illustrations.
  * Do not substitute non-kit components for any of the components from the kit for administration.



Preparation

  1. At least 60 minutes prior to administration, remove the SUSTOL kit from refrigeration.
  2. Unpack the kit to allow the SUSTOL syringe and all other contents to warm to room temperature.
  3. Activate one of the syringe warming pouches, and wrap the SUSTOL syringe in the warming pouch for 5 to 6 minutes to warm SUSTOL to body temperature.
  4. Prior to administration, inspect the SUSTOL syringe visually for particulate matter and discoloration. Note that the syringe is amber colored glass. SUSTOL should not be administered if particulate matter or discoloration is observed, the tip cap is missing or has been tampered with, or if the Luer fitting is missing or dislodged.



Administration

  1. Use standard aseptic technique when performing the injection.
  2. Administer SUSTOL as a single subcutaneous injection in the skin of the back of the upper arm or in the skin of the abdomen at least one inch away from the umbilicus. Avoid injecting SUSTOL anywhere the skin is burned, hardened, inflamed, swollen, or otherwise compromised [see Warnings and Precautions (5.1)]. Topical anesthetic may be used at the injection site prior to administration of SUSTOL.
  3. Due to the viscosity of SUSTOL, the time required for injection is greater than most medications administered subcutaneously. SUSTOL requires a slow, sustained injection which may take up to 20 to 30 seconds. Pressing the plunger harder will NOT expel SUSTOL faster.
PROBLEM TO BE SOLVED: To obtain the subject therapeutic agent for restraining or delaying the onset of insulin nondependent diabetes or complications thereof found in a population which has experienced glucose tolerance insufficiency by including a methylpyridylaminoethoxybenzylthiazolidinedione. SOLUTION: This therapeutic agent contains a therapeutically effective amount of 5- 4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl}thiazolidine-2,4-dione Preferably, this compound is included together with a pharmaceutically acceptable vehicle, diluent or support. The amount of the active ingredient in a unit dose of the preparation is pref. 0.1-100 mg. more pref. 0.5-100 mg, the daily dose of the active ingredient being pref. about 0.01-10 mg/kg body weight.